Analysts downgraded revenue forecasts for Akoya Biosciences (NASDAQ:AKYA) signaling a weaker outlook. Revenue estimates were cut sharply, with a 14% projected sales growth in 2025.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Time To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) Outlook
